Syngene International Limited
Government of Singapore decreased its stake in Syngene International Limited from 2.89% to 2.13%, selling 3,026,632 shares. The value of the remaining stake is approximately ₹350 crore.
India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.
Singapore sovereign investor (GIC), managing the Government of Singapore's foreign reserves. One of the world's largest SWFs with significant Indian equity holdings.